Clinical trial
Doxil and Gemcitabine in Recurrent Ovarian Cancer
NCT00312650 · Women and Infants Hospital of Rhode Island, Other · Terminated
Key facts
| NCT number | NCT00312650 |
|---|---|
| Title | Doxil and Gemcitabine in Recurrent Ovarian Cancer |
| Official title | A Phase II Study of Every 2 Week Doxil and Gemcitabine in Recurrent Ovarian Cancer |
| Lead sponsor | Women and Infants Hospital of Rhode Island, Other |
| Collaborators | Ortho Biotech, Inc. Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Carcinoma |
| Intervention type | Drug |
| Interventions | liposomal doxorubicin and gemcitabine |
| Enrollment | 24 |
| Start date | Apr 1, 2006 |
| Primary completion | May 1, 2006 |
| Completion | May 1, 2006 |
| First posted | Apr 10, 2006 |
| Last update posted | Jan 12, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: